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Abstract
The NINDS trial demonstrated for the first time the effectiveness of intravenous
thrombolysis in improving outcome after acute ischemic stroke. The absolute
benefit of this intervention was 11-13% greater chance of being normal or near
normal (MRS ≤ 1) at 3 months. However, if patients with severe stroke were
considered (NIHSS ≥ 20), the absolute benefit dropped to 5-6%, indicating that
IV thrombolysis may not be as effective for large vessel occlusion. This
observation was further supported by TCD studies that clearly demonstrated
that large artery occlusions had a recanalization rate of 13-18% with IV rt-PA.
Intra-arterial thrombolysis achieves recanalization rates of 60-70%. Since tissue
viability is clearly important, it is time to stop defining rigid time windows and
if there is a large penumbra (20-50%) and the occlusion is in a large artery, there
exists a logic and a growing evidence to consider either bridge therapy or direct
intra-arterial therapy.
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Introduction 
The range of treatments available for acute ischemic stroke (AIS) has
expanded considerably in recent years. Dynamic advances in neuroimaging
techniques and improved understanding of the pathophysiology of stroke
have changed the nihilistic approach of the past to one of hope, resolve
and commitment. In general, the timing of various therapeutic
interventions is limited to the evolution of the ischemic process. There is
a great deal of emerging evidence that may suggest that the duration of
the ischemic penumbra varies considerably [1, 2]. This may depend on
factors such as the underlying mechanisms of ischemia and the rate of
recanalization. There is evidence that the ischemic penumbra may persist
for up to 48 h after onset, but in some cases it may be 3 h or even less.
The survival of the bulk of ischemic tissue is dependent on early energy
failure and ionic imbalances, and smaller volumes are dependent on
neurotoxic, inflammatory processes and on apoptosis. 
Review
Thrombolytic therapy is an inherently attractive treatment for AIS based
on known pathologic and angiographic substrates of ischemic
cerebrovascular disease. Most ischemic strokes are the direct consequence
of atherothrombosis or a thromboembolism of a cerebral or precerebral
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artery. The critical event is usually the formation of
an acute thrombus [3, 4]. The basis for thrombolytic
treatment is to achieve rapid arterial recanalization
with a relatively safe agent soon enough to improve
patient outcome. 
Intra-venous thrombolysis
Prompt reperfusion strategies such as intra-
venous (IV) recombinant tissue plasminogen
activator (rTPA) have provided clinicians with
a potent weapon in the armamentarium against
AIS, but with clear limitations [5]. The evidence for
efficacy is strong and fulfils level I criteria.
Cumulative evidence from all trials of tPA within the
3-h time window gives a relative risk reduction of
44%, absolute risk reduction (ARR) of 13% and
number needed to treat (NNT) to save one person
from death or disability about 7 [5]. This is
a powerful biologic effect and its extent is often
under-recognized. To counter this, there is only
a modest and non-significant increase in mortality,
but an approximately 3-fold increase in intra-cranial
hemorrhage (ICH) [5]. 
However, only a very small percentage of
patients with AIS receive IV rTPA, partly related to
the very narrow therapeutic time window for
intervention, and multiple, stringent exclusion
criteria. Furthermore, IV rTPA results in recana  -
lization in approximately 50% of patients. Patients
treated within 90 min did better than those treated
after 90 min within the 3-h window [6]. This
difference was significant and suggests that earlier
treatment is associated with a better outcome.
When analyzed by stroke severity, the magnitude
of benefit declined with increasing NIHSS scores.
Patients with NIHSS scores > 20 had a ≤ 6% ARR in
achieving mRS < 1 at 90 days as against a 13% ARR
in patients with NIHSS scores of < 20 [5]. This
suggests that patients with large vessel occlusions
with a high clot burden, as would be expected with
the internal carotid artery (ICA), main stem middle
cerebral artery (M1), or basilar artery (BA), are less
likely to improve with the present accepted and
FDA-approved IV thrombolysis strategy. NINDS
unfortunately did not have vascular imaging, and
had a relatively low NIHSS, in the group treated
between 91-180 min (≤ 15  = tPA arm  = 60.2%;
placebo  = 52.7%; ≥ tPA arm  = 39.9%; placebo arm
= 47.3%) (Table I), suggesting that even the large
vessel strokes in NINDS were probably branch
occlusions and not main middle cerebral artery
(MCA), internal carotid artery (ICA) or basilar artery
occlusions [7]. Patients treated from 91 to 180 min
after stroke onset had far less severe strokes than
the control (placebo) group. More tPA-treated
patients had mild strokes (15% difference),and
fewer had severe strokes (10% difference). Those
differences are significant in absolute terms, but
their actual significance becomes apparent when
the importance of the graph from the TOAST study
(Trial of Org 10172 in Acute Stroke Treatment) is fully
appreciated [8]. The graph plots the probability of
an excellent outcome of an untreated stroke patient
against the baseline NIHSS score. The curves are
flat at high baseline NIHSS scores above 20, and
stroke patients with a baseline NIHSS score of over
20 have a low probability of an excellent outcome
(< 10% favorable outcome rate). While this does not
automatically translate to a better outcome with
intra-arterial thrombolysis in patients with NIHSS
scores > 20 (who may [but not necessarily] have
large vessel occlusions and hence a more severe
NIHSS score), the observations suggest that mere
IV thrombolysis may not be effective in this group
of patients. 
There has been a relative lack of efficacy of IV
rTPA when given after 3 h of stroke (European
Cooperative Acute Stroke Studies [ECASS I and
ECASS II]; Alteplase Thrombolysis for Acute Non-
interventional Therapy in Ischemic Stroke
[ATLANTIS]) [9-12]. A high rate of symptomatic brain
hemorrhage was noted in ATLANTIS. A meta-
analysis, however, showed benefit from IV therapy
up to at least 4.5 h. The recently published results
of the ECASS III study confirm the advantage of
giving IV rTPA up to 4.5 h after stroke onset. 
ECASS III tested the efficacy and safety of alteplase
administered between 3 and 4.5 h after the onset
of stroke [13]. 
Patients were randomly assigned in a 1 : 1 dou  -
ble-blind fashion to receive treatment with
intravenous alteplase (0.9 mg per kg of body
weight) or placebo. The primary end point was
disability at 90 days, dichotomized as a favorable
outcome (a score of 0 or 1 on the modified Rankin
scale, which has a range of 0 to 6, with 0 indicating
no symptoms at all and 6 indicating death) or an
unfavorable outcome (a score of 2 to 6 on the
modified Rankin scale). The secondary end point
was a global outcome analysis of four neurologic
Baseline   tPA-Treated    Patients 
NIHSS score   patients,   given placebo, 
% (n = 153) % (n = 167) 
0-5 19.0 4.2 
6-10 24.2 27.5 
11-15 17.0 21.0 
16-20 21.6 19.8 
> 20 8.3 27.5 
tPA – tissue plasminogen activator, *From Marler et al. 
Table I. Percentage of patients (n = 320) in the 91 to
180-min subgroups with a specific baseline National
Institutes of Health Stroke Scale (NIHSS) score* Arch Med Sci 3, June / 2010 305
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and disability scores combined. Safety end points
included death, symptomatic intracranial hemor  -
rhage, and other serious adverse events. Out 
of a total of 821 patients in the study, 418 randomly
assigned to the rTPA group and 403 to the placebo
group, median time for the administration of rTPA
was 3 h 59 min. More patients had a favorable
outcome with rTPA than with placebo (52.4% vs.
45.2%; odds ratio 1.34; 95% confidence interval [CI]
1.02 to 1.76, p = 0.04). In the global analysis, the
outcome was also improved with rTPA as compared
with placebo (odds ratio 1.28, 95% CI 1.00 to 1.65, 
p < 0.05). The incidence of intracranial hemor  -
rhage was higher with rTPA than with placebo 
(for any intracranial hemorrhage, 27.0% vs. 17.6%,
p = 0.001; for symptomatic intracranial hemorrhage,
2.4% vs. 0.2%; p = 0.008). Mortality did not differ
significantly between the rTPA and placebo groups
(7.7% and 8.4%, respectively; p = 0.68). There was
no significant difference in the rate of other serious
adverse events [13].
What are the advantages/limitations 
of intra-venous thrombolysis alone? 
The main limitations of IV rTPA include its
inability to provide any diagnostic information,
a short time window for use, inadequate
recanalization rates, and poor specificity for the site
of arterial occlusion. The advantages of IV rTPA
remain its relative ease of administration,
widespread availability, and proven efficacy within
3/4.5 h of AIS. 
In angiographically based studies, recanalization
of the ICA and MCA was rare after intravenous
thrombolysis [14-16]. Recent studies that evaluated
the response to intravenous rTPA using transcranial
Doppler or CT angiography suggest that only 13%
to 18% of patients with proximal MCA occlusions
recanalize after administration of intravenous rTPA
[17, 18]. Lee et al. demonstrated recanalization of
major vessel occlusions only in 23% of patients [17].
If recanalization is taken as an important
prerequisite for better stroke outcome, IV throm  -
bolysis for major vessel occlusions such as MCA,
ICA or basilar arteries is not justified as the optimal
strategy. Although recanalization does not
automatically translate into good stroke outcome
and other factors such as time of intervention,
collateral supply, degree of stroke severity, and co-
morbid conditions play a major role, prompt
reperfusion retains its paramount importance. While
the only imaging required before giving rTPA is
a noncontrast head CT, to remain time efficient, it
leaves much to be desired in terms of diagnostic
accuracy of clot location, ischemic penumbra,
collateral blood flow, and potential time window for
efficacy of treatment. Therefore, although
expediency of treatment is paramount for
improving outcome, in patients with occlusion of
the internal carotid artery (ICA) or M1 segment of
the MCA, systemic thrombolysis may not be capable
of achieving vessel recanalization due to the large
clot burden. Can we do better with IA thrombolysis
or combined IA/IV thrombolysis or combined
IV/mechanical and other endovascular thrombolysis
in these patients with large vessel occlusion, even
if they present within 3 h of stroke onset? This
precludes the FDA approval and the stroke
guidelines. The argument in favor is given below. 
Intra-arterial thrombolysis
Recent advances in the field of neuro  -
interventional radiology, with the development of
extremely soft, compliant microcatheters and
steerable microguide wires, along with high contrast
agents, have made it feasible and safe to access the
major intracranial blood vessels around the Circle
of Willis from a percutaneous transfemoral
approach under local anaesthesia. Intra-arterial
thrombolysis has been used most successfully in
patients with acute MCA occlusion. Trials have used
IA thrombolysis to at least 6 h from stroke onset in
patients with MCA occlusion. Other potential
candidates for IA thrombolysis include patients with
extracranial carotid artery occlusion, intracranial
carotid artery T occlusion and basilar artery
occlusion. 
Thrombolytic agents used for IA thrombolysis
have been rTPA, urokinase (UK), pro-urokinase 
(scu-PA), reteplase, desmoteplase, tenecteplase
(TNK), streptokinase, staphylokinase, plasmin, and
microplasmin [19-41]. 
Compared to IV therapy, localized IA thrombolysis
has the theoretical advantage of achieving more
complete recanalization with less fibrinolytic drug,
and clot lysis can be assessed with follow-up
angiograms. Drug infusion can be stopped when
clot lysis is achieved, leading to potentially less
thrombolytic drug being used. Finally, with IA
thrombolysis, treatment has been initiated up to 
6 h after symptom onset. This generally expands
the time window, which increases the number of
patients who potentially can benefit from
thrombolysis beyond the time limit of 3 h or
perhaps 4.5 h (as is evidenced from the European
Co-operative Acute Stroke Study – ECASS III trial
results [13]). 
Two randomized trials comparing IA recombinant
pro-urokinase (r-pro-UK) plus IV heparin vs. IV
heparin have been conducted in patients with
occlusion of the MCA (M1 and M2) of < 6 h’
duration. In the Prolyse in Acute Cerebral
Thromboembolism (PROACT) I trial [19], 40 patients
with MCA occlusion were treated with either IA 
r-pro-UK (n = 26) or placebo (n = 14). All patients
received IV heparin. The protocol initially specified306 Arch Med Sci 3, June / 2010
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a heparin dose of a 100 IU/kg bolus and an infusion
of 1000 U/h for 4 h. After 16 patients were
randomized, the heparin dose was reduced 
to a 2000 IU bolus and an infusion of 500 IU/h 
for 4 h on the recommendations of the safety
committee. The study drug was started on average
5.5 h after the onset of symptoms. Recanalization
rates were significantly higher with r-pro-UK (58%)
than with placebo (14%; 2-sided p = 0.017). There
was no significant difference in the rate of early
symptomatic hemorrhagic transformation, which
occurred in 15.4% of the r-pro-UK patients and 7.1%
of the placebo-treated patients (2p = 0.64). Ninety-
day mortality rates (4% in the pro-UK group vs. 
7% in the control group) and good clinical outcomes
(30.4% vs. 21.4%) favored treatment with r-pro-UK
but did not reach statistical significance [19].
Recanalization rates and the risk of brain hemorrhage
were influenced by the dose of heparin [19]. 
The PROACT II study [20] was designed to further
test the efficacy and safety of IA r-pro-UK in
patients with MCA occlusion of < 6 h duration. More
than 1200 patients were evaluated for inclusion in
the trial and 474 patients underwent conventional
cerebral angiogram screening. One hundred eighty
patients had angiogram-confirmed MCA occlusions
and were randomized to receive 9 mg of IA r-pro-
UK plus heparin (n = 121) or heparin alone (n = 59).
The heparin dose was the same in both groups
(2000 U bolus and a 500 U/h infusion of heparin
for 4 h). A clinically and statistically significant
benefit favored r-pro-UK in the primary outcome
analysis, with 40% of the treated patients
recovering to an mRS of ≤ 2 compared with 25% of
control patients (ARR 15%, p = 0.043, relative risk
reduction 60%). Mortality was 25% in the r-pro-UK
group and 27% in the control group. Symptomatic
intracranial hemorrhage (ICH) occurred in 10% 
of the r-pro-UK group and 2% of IN controls 
(p = 0.063). The recanalization rate (thrombolysis
in myocardial infarction 2 or 3) was 66% for those
on r-pro-UK vs. 18% for the controls (p < 0.001).
Patients recruited in PROACT II had moderate-to-
severe strokes with a median baseline NIHSS of 17.
The median time to start IA treatment was 5.3 h.
The benefits of r-pro-UK were maximal in patients
with baseline NIHSS scores of 11-20 [20]. 
The Middle Cerebral Artery Embolism Local
Fibrinolytic Intervention Trial (MELT) randomized 114
patients in Japan with MCA stroke within 6 h to IA
UK or standard therapy [42]. No intravenous
thrombolysis was allowed in either group.
Adjunctive mechanical disruption of clot was
allowed in the UK group. The study was stopped
prematurely once IV thrombolysis was approved in
Japan. The primary endpoint of favorable outcome
(mRS 0-2) at 90 days occurred more often in the IA
group (49.1% vs. 38.6%, OR 1.54, 95% CI 0.73 to
3.23, p = 0.345), but was not statistically significant.
The preplanned secondary endpoint of excellent
outcome (mRS 0-1) at 90 days was significantly
higher in the UK group (42.1% vs. 22.8%, OR 2.46,
95% CI 1.09 to 5.54, p = 0.045). It should be noted
that the MELT trial randomized patients with
a lower baseline stroke severity compared to the
PROACT II trial (NIHSS 14 vs. 17) and treated patients
earlier; this may partially explain the lack of
statistical significance for the primary endpoint
(mRS 0-2 at 90 days) in the MELT trial. Furthermore,
the MELT study may have been underpowered to
detect a difference between groups due to the
premature termination of the study once IV
thrombolysis became available in Japan [43]. 
Ducrocq et al. conducted a small randomized
multicenter trial comparing IV UK vs. IA UK given
within the first 6 h of AIS [44]. Patients received
900,000 U of UK via IV (n = 14) or IA (n = 13) routes.
Due to safety concerns the study was stopped early.
A total of 7 patients (26%) died: 4 in the IV group
and 3 in the IA group. Although the authors
reported a greater and earlier improvement in the
IA group, there was no difference in the main
outcomes studied. 
It is unclear whether IA thrombolysis or IV
thrombolysis is more effective for ischemic stroke
with hyperdense middle cerebral artery sign (HMCAS)
on computed tomography (CT). Mattle et al. [45]
compared IA thrombolysis and IV thrombolysis in
stroke patients with HMCAS. The comparison of
data was from 2 stroke units with similar
management of stroke associated with HMCAS,
except that 1 unit performed IAT with urokinase and
the other IVT with plasminogen activator. Time to
treatment was up to 6 h for IA thrombolysis and up
to 3 h for IV thrombolysis. Outcome was measured
by mortality and the modified Rankin Scale (mRS),
dichotomized at 3 months into favorable 
(mRS 0 to 2) and unfavorable (mRS 3 to 6). One
hundred twelve patients exhibited a HMCAS, of
whom 55 were treated with IA thrombolysis and 57
with IV thrombolysis. Stroke severity at baseline and
patient age were similar in both groups. Mean time
to treatment was longer in the IA thrombolysis
group (244 ±63 min) than in the IV thrombolysis
group (156 ±21 min, p = 0.0001). However, favorable
outcome was more frequent after IA thrombolysis
(n = 29, 53%) than after IV thrombolysis (n = 13,
23%, p = 0.001), and mortality was lower after IA
thrombolysis (n = 4, 7%) than after IV thrombolysis
(n = 13, 23%, p = 0.022). After multiple regression
analysis IA thrombolysis was associated with a more
favorable outcome than IV thrombolysis 
(p = 0.003) but with similar mortality (p = 0.192). In
this observational study IA thrombolysis was more
beneficial than IV thrombolysis in the specific group
of stroke patients presenting with HMCAS on CT,Arch Med Sci 3, June / 2010 307
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even though IA thrombolysis was started later. Their
results indicate that a randomized trial comparing
both thrombolytic treatments in patients with
middle cerebral artery occlusion is warranted [45]. 
Quershi et al. [46], however, found favorable
results even in patients with HMCAS thrombolyzed
intravenously within 3 h of stroke onset. Class 1b
angiographic proof for reperfusion and good
outcomes for large vessel came from the PROACT II
trial [20]. 
Despite the findings of PROACT II the FDA did not
approve proUK for use. Because proUK is not
commercially available, most interventional neuro  -
radiologists use UK or rTPA when performing 
IA thrombolysis. No randomized controlled trials of IA
thrombolysis with rTPA for acute stroke have been
performed. The results of IA thrombolysis using t-PA
or UK in selected patients have generally been
favorable, or clinical outcomes have been better than
anticipated, despite increases in the rate of
symptomatic ICH. Several retrospective studies have
suggested that IA thrombolysis is superior to IV
thrombolysis in patients with ICA, BA or M1 occlusions
associated with the dense MCA sign. A few smaller
studies of ICA or BA occlusion suggest the superiority
of IA thrombolysis over IV thrombolysis. Furthermore,
even though data on reopening major arterial
occlusion after AIS with devices is mainly registry
based, the results are comparable to those reported
in the PROACT study without a significant increase in
symptomatic hemorrhage.
Intra-arterial thrombolysis 
in the vertebrobasilar territory 
The natural history of basilar artery occlusion is
extremely poor, with mortality ranging from 83% to
91% [47]. Basilar artery occlusion is usually due to
atherothrombosis. There is a high incidence of
residual stenosis after basilar artery recanalization,
which often requires adjuvant therapies including
angioplasty, antithrombotic and antiplatelet agents,
and stenting. Good clinical outcomes are strongly
associated with recanalization after thrombolytic
therapy. Hacke et al. described 65 consecutive
patients with vertebrobasilar occlusions treated
either with local IA UK or IA streptokinase (SK) plus
heparin (n = 43) or conventional antiplatelet/
anticoagulation therapy (n = 22) [48]. The re  -
canalization rate in thrombolysis patients was 
44% (19 of 43). All patients without recanalization
died whereas 14 of 19 patients with recanalization
survived, and 10 had a favorable outcome. The
mortality rate with conventional therapy was 86%
compared to 67% with thrombolysis. The rate of
brain hemorrhage with clinical deterioration was
7% in patients who underwent thrombolysis [48]. 
Recanalization rates depend on the location of
the vertebrobasilar occlusion (VBO) [48-50]. Distal
basilar occlusions have higher recanalization rates
than proximal ones. The timing of IA vertebrobasilar
thrombolysis is often a difficult decision. The
presence of coma or tetraparesis for several hours
portends a poor prognosis despite recanalization.
Such symptoms however may not preclude survival,
and recovery has been documented after successful
recanalization in such patients. 
The time window for thrombolysis may be longer
in VBO, with many series reporting time-window
durations of up to 24 h, 48 h and even 72 h after
symptom onset in patients with stuttering courses.
Some studies suggested good outcomes in patients
receiving even delayed treatment. A longer time
window may be due to a higher ischaemic tolerance
or improved collateralization in the posterior
circulation [47]. Cross et al. [51], reporting on 20
patients with basilar artery thrombosis who
received IA thrombolysis, found that better collateral
blood flow was correlated with improved responses
to thrombolysis and with longer tolerance of
ischaemia. Patients with proximal basilar artery
thrombosis did not seem to have the same benefit.
Patients with vertebrobasilar ischaemia often have
chronic atherosclerotic disease which allows
collaterals to develop over time. 
There may be two distinct populations of
patients with VBO as hypothesized by Cross [51].
Patients with a progressive stuttering course may
have improved collateral circulation and better
outcomes despite later treatment than patients
with sudden onset of severe deficits owing to poor
collaterals, even though they may be brought to
treatment earlier. Superselective IA angiography
and local IA administration of thrombolytic agents
is now considered most optimal for more complete
recanalization of acute basilar thrombus. Complete
reperfusion of the posterior circulation is taken as
a conditional sine qua non for the most favorable
stroke outcome after basilar artery occlusion. There
are arguments raised that although optimal, this
procedure requires expertise and adequate
infrastructure which makes it amenable only to
a few selected centers. 
Combined intra-venous and intra-arterial
thrombolysis
One major disadvantage of IA thrombolysis is
the delay to treatment because of the waiting
period for initiation and performance of cerebral
angiography. The Emergency Management of Stroke
(EMS) Study [52] and the Interventional
Management of Stroke (IMS) Trial [53] combined IV
and IA thrombolysis. This approach combines the
advantages of 2 treatment strategies. IV therapy is
initiated without delay but at a lower dose, which
allows some of the tPA to be given intra-arterially
for the higher recanalization rates that potentially308 Arch Med Sci 3, June / 2010
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can be achieved with IA treatment. The EMS or the
Bridging Trial randomized 35 patients to either
combination IV/IA thrombolysis (n = 17) or
placebo/IA thrombolysis (n = 18) within 3 h of onset
of symptoms. Complete recanalization rates were
better in the combination IV/IA group (6/11) vs. the
placebo/IA group (1/10) (p = 0.03); however,
neurological outcomes at 90 days did not differ
between groups. The mortality rate trend was
higher in the combination (IV/IA) group (29%) vs.
the placebo/IA group (5.5%) (p = 0.06). The small
sample size of this study precluded any definitive
conclusions [48]. The EMS trial demonstrated that
the combined approach is feasible, reasonably safe,
and worthy of further study [52]. Although the
Interventional Management Study (IMS II) [53],
a trial that combined IV and IA therapy, was
considered a negative trial in terms of the primary
outcome, the group treated with combined IV and
IA therapy had a better outcome than the placebo
treated patients of the NINDS trial and if secondary
outcome measures were considered (Barthel Index
and the Global Scale), a statistically better outcome
was seen with combined therapy compared to the
IV treated group of the NINDS trial. Of the 74
patients who underwent an angiogram after
receiving IV rt-PA (0.6 mg/kg with a 15% bolus), the
majority achieved a TIMI grade 2-3 flow after
additional IA thrombolysis (43% treated within 3 h
and 13% between 3-4 h). Of the 28 patients with
ICA occlusion, 56% achieved a TIMI reflow of 2-3,
which correlated with the outcome of a mRS ≤ 1.
Of the remaining patients with ICA occlusions who
had a TIMI of 0-1, only 12% had a similar good
outcome. Two important conclusions can be drawn
from the IMS II trial. Firstly, recanalization was
achieved only after rescue IA therapy in the majority
of patients. Secondly, those patients treated with
the combined therapy within 3 h had a significantly
better outcome than those treated within the 3-4 h
window. Whether we can do better with the
combined or operator-based selected device and/or
thrombolysis remains a question that will hopefully
be answered by the 2 ongoing trials, Interventional
Management Study 3 (IMS 3) and MR RESCUE. 
What are the limitations of intra-arterial
thrombolysis? 
The main disadvantages of IA thrombolysis are
the logistic factors involved such as the need to
assemble the angiography team and confirm
occlusion angiographically before administration of
thrombolysis. Once IA therapy commences, the
average time to recanalization ranges from 1.9-2.8 h
[46]. One approach to minimize the delay in
thrombolysis using IA therapy is to use a com  -
bination of a reduced dose of IV rTPA (0.6 mg/kg)
within 3 h and then continue therapy using 
IA thrombolysis in patients who do not respond to
IV thrombolysis. The other potential disadvantage
of IA thrombolysis is the invasiveness of
angiography and the expertise required. It will be
unlikely that routine IA thrombolysis will be feasible
in most practice settings. Although the risk of
serious complications is relatively low, in a large
retrospective analysis of about 20,000 patients who
underwent cerebral angiography at the Mayo clinic,
stroke and death occurred in 0.15% and 0.06% of
patients, respectively [54]. Other complications
include access-site hematoma (4.2%); nausea,
vomiting or transient hypotension (1.2%); ana  -
phylaxis (0.03%); and acute renal failure (0.04%).
Stroke occurred more frequently in patients with
underlying atherosclerotic disease (0.25%) [54]. The
relative costs of IA vs. IV thrombolysis have not been
reported but it is logical to assume that the direct
cost of treatment with IA thrombolysis would be
higher. However, when the long-term implications
of stroke mortality and morbidity are considered,
these cost implications may be better for IA
thrombolysis. 
Newer thrombolytic agents 
One of the 2 major problems in crossing the 
3-h time window is the propensity for ICH. Several
second- and third-generation thrombolytic agents
(tenecteplase, reteplase, desmoteplase, plasmin,
microplasmin) are being tested. The goal is to create
new thrombolytic agents with longer half-lives that
permit bolus administration, and have better rates
of restoration of flow and reduced rates of ICH. 
Desmoteplase: The recently completed phase II
trial Desmoteplase in Acute Stroke study (DIAS) of
an rt-PA molecule derived from bat saliva used
diffusion/perfusion MRI to enroll patients and
assess the biological activity of different doses [27].
Patients were included in the study between 3 and
9 h after stroke onset, if they demonstrated
a perfusion lesion volume ≥ 20% above the baseline
diffusion lesion volume. Magnetic resonance
angiography (MRA) was also performed and all 
3 MRI modalities were repeated several hours after
completion of thrombolytic therapy to evaluate the
efficacy of reperfusion. Lower weight-adjusted
dosing demonstrated a reasonable safety profile
and dramatic reperfusion efficacy. Clinical outcomes
tended to be more favorable in treated patients as
well. This pilot study is important because it
confirms the safety of weight-adjusted des  -
moteplase in ischaemic stroke patients when
administered up to 9 h after stroke onset, as well
as the intended biological effect of inducing
reperfusion [26, 27]. 
Tenecteplase: TNK-tPA is a more fibrin-specific
variant of t-PA. It also has a longer half-life and
increased resistance to plasminogen activatorArch Med Sci 3, June / 2010 309
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inhibitor type 1 (PAI-1) which allows for dosing as
a single bolus. Pilot studies are under way to test
its efficacy [24]. 
Combination of adjunctive therapy 
with thrombolysis 
Glycoprotein (Gp) IIb/IIIa inhibitors block the final
common pathway of platelet aggregation, and have
demonstrated efficacy in preventing thrombus
formation in acute coronary syndromes and
percutaneous coronary interventions (PCIs). In acute
ischemic stroke, a dose-escalation study demon  -
strated that the Gp IIb/IIIa inhibitor abciximab 
is safe when given as a 0.25 mg/kg bolus and 
0.125 mg/kg/min infusion. The Emergent Stroke
Treatment Trial (ABESTT) study [55] suggests
a possible efficacy of abciximab in acute stroke with
a longer therapeutic window and a better safety
profile than rt-PA given within 3 h. A phase II trial
is under way in AIS of < 6 h duration. Some centers
use Gp IIb/IIIa inhibitors as adjunctive therapy with
IA thrombolysis in AIS [35]. There are also reports
of acute intervention with angioplasty and stenting.
Some trials are underway using ultrasound waves
as an adjunct to better lyse the clot when using IV
or IA thrombolysis. The Neuroflo Catheter is an
endovascular device that is in clinical study. It uses
inflatable balloons that are placed in the abdominal
aorta to augment cerebral blood flow without
increasing blood pressure; randomized controlled
trials are underway to assess the utility of this
therapy. Several catheters that control body
temperature and induce hypothermia for the
treatment of stroke are also currently under
investigation. Data are not adequate to comment
further on their safety or efficacy. 
Mechanical clot lysis 
Mechanical approaches to ischemic stroke are
attractive because they may obviate the need for
thrombolytic drugs which increase the risk of
reperfusion hemorrhage. The AngioJet catheter has
been used to fragment and suck in the clot. It uses
a high-velocity stream of saline directed back into
the catheter to create a localized low-pressure zone
at the distal tip. The thrombus is trapped, broken
into small particles and evacuated within minutes
via the Bernoulli effect. The system is currently used
in saphenous vein graft thrombectomy but has also
been modified for neurovascular use. Distal
embolization of particles is of potential concern.
Other means of delivering energy to fragment the
clot are being developed, including use of
ultrasound and laser devices. The current limitation
of these mechanical devices is their relatively large
catheter size and less flexibility, which limit access
to the tortuous vessels of the intracranial
circulation. The Mechanical Embolus Removal in
Cerebral Ischemia (MERCI) Trial evaluated the safety
of the MERCI Retriever System [56]. MERCI trial was
a nonrandomized study using historical controls
from PROACT II [20]. This study included patients
with an occlusion of a major vessel who could be
treated within 8 h of symptom onset. The primary
goal of the MERCI study was to achieve
a recanalization rate greater than seen in the
control arm of PROACT II (18%). A total of 151 rTPA-
ineligible patients were enrolled in the MERCI trial,
and the device was deployed in 141 of these
patients; recanalization occurred in 48% of treated
patients, a percentage that is significantly greater
than the spontaneous recanalization rate seen in
PROACT II (p < 0.0001). The neurologic outcome was
a secondary outcome measure in this study and
was assessed by comparing the outcome of
patients undergoing mechanical thrombectomy
with that of patients in the control arm of PROACT II.
In comparison to PROACT II, mortality was not
decreased in the MERCI trial, although MERCI
patients appeared to have more severe strokes
(Table II – compares data from PROACT II, MERCI,
IMS I, IMS II with patients in the NINDS study who
have an NIHSS of 10 or more [57]). In fact, mortality
appeared to be increased (54.2%) in patients who
could not be recanalized, suggesting that the
procedure may harm this population. 
The Multi MERCI trial was the follow up to
MERCI. This trial included patients who received
intravenous rTPA within 3 h time window but had
persistent vessel occlusion. Patients who were rTPA-
ineligible were also included [58, 59]. Patients had
to be treated within 8 h of stroke onset. The main
finding of this study supports the safety for
mechanical thrombectomy in patients who had
already received intravenous rTPA according to the
FDA-approved indications. The study results suggest
that “rescue therapy” with the MERCI Retriever may
be considered for patients who fail to recanalize
after intravenous thrombolytic therapy. MERCI
patients had more severe stroke (median NIHSS = 19)
and comprised a more heterogeneous stroke
population than did the patients in either PROACT II
or the NINDS rTPA trial, which limits the validity of
the comparison of these trials. However, based on
the design and findings of the MERCI trial, it
appears that the device is capable of recanalizing
blood vessels in patients with stroke. These trials
however do not provide definitive evidence that
treatment with the Merci Retriever improves
neurologic outcome. 
A few other smaller studies such as EKOS,
TRUMBI and CLOT BUST [60] evaluated the
additional benefits of using thrombolytics in
combination with exposure to ultrasound.
Theoretically, this approach would increase the310 Arch Med Sci 3, June / 2010
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IA vs. IV thrombolysis for stroke 
accessibility of the drug to the clot. Using the
same protocol as IMS I, the IMS II study evaluated
a new approach to recanalization using the novel
endovascular device known as the EKOS Neuro
Wave Catheter [53], along with IA rTPA infusion.
Among patients treated with IA rTPA and the
EKOS Neuro Wave Catheter, 73% of the vessels
were recanalized at the end of the procedure
(compared with 56% in the IMS I). Based on these
data, an NIH-funded phase III trial is underway
to compare intravenous thrombolysis with
a combined approach using a modified dose/
administration protocol for intravenous rTPA
followed by an attempt at recanalization using IA
thrombolysis and other endovascular techniques,
including mechanical thrombectomy (with the
Merci Retriever) and the EKOS Neuro Wave
Catheter. 
The safety and performance of the Penumbra
System (PS), a novel mechanical device designed
to reduce clot burden in acute stroke due to large-
vessel occlusive disease was tested in a prospective,
single arm, independently monitored and core
laboratory adjudicated trial which enrolled subjects
with acute ischemic stroke, presenting within 8 h
of symptom onset and an angiographically verified
occlusion (Thrombolysis in Myocardial Infarction
[TIMI] grade 0 or 1) of a treatable intracranial vessel
[61]. The primary end point was revascularization
of the target vessel to TIMI grade 2 or 3. Secondary
end points were the proportion of subjects who
achieved a mRS score of 2 or less or a 4-point
improvement on the NIHSS score at 30-day follow-
up, as well as all-cause mortality. Of the 23 patients
enrolled, and 21 target vessels treated in 20
subjects by the PS, (mean age = 60 years, mean
mRS score = 4.6, and mean NIHSS score = 21), all
21 of the treated vessels (100%) were successfully
revascularized by the PS to TIMI 2 or 3. At 30-day
follow-up, 9 subjects (45%) had a 4-point or more
NIHSS improvement or an mRS of 2 or less. The all-
cause mortality rate was 45% (9 of 20), which is
lower than expected in this severe stroke cohort,
where 70% of the subjects at baseline had either
an NIHSS score of more than 20 or a basilar
occlusion [61]. Following this study PS has also been
approved by the FDA for clinical use. 
Reperfusion strategies in stroke subtypes 
Use of aggressive interventional strategies is
often advocated for basilar artery thrombosis,
considering the devastating mortality and morbidity
associated with it. However, intervention in patients
who have been quadriplegic or deeply comatose for
more than 3 h does not portend a good recovery
[62]. The Basilar Artery Interventional Cooperation
Study is a prospective, nonrandomized study that
will compare outcomes among patients who receive
antithrombotics, intravenous thrombolytics, and
endovascular therapy. 
Patients with ICA occlusion rarely experience
good recanalization with IV thrombolysis [12, 63,
64]. In MERCI and Multi MERCI trials, out of the 80
patients with carotid occlusion, 53% were
recanalized with mechanical thrombectomy alone
and 63% were recanalized with mechanical
thrombectomy and adjunctive endovascular
therapy [65]. Good clinical outcome (modified
Rankin Score [mRS] ≤ 2) was achieved in 39% with
recanalization and in 3% without recanalization
emphasizing the concept that recanalization may
not the sole but an inherently important component
for achieving neurological recovery [65]. Mortality
was 30% in the recanalized group and 73% in the
non-recanalized group [65]. 
Expanding the therapeutic time window
After vascular occlusion, there is a hetero  -
geneous depression of cerebral blood flow (CBF) in
the territory of the occluded artery. The penumbra
is identified as the brain region receiving regional
CBF (rCBF) between two critical values. The first,
higher critical value, is associated with neuronal
paralysis: brain areas receiving rCBF less than 
18-20 ml/100 g/min do not function. The second,
lower critical value, is associated with cell death;
brain areas receiving less than 8-10 in ml/100 g/min
do not survive, and this area becomes the core of
the infarction [1, 2]. Neurons in the penumbra are
sometimes identified as idling to suggest that they
are salvageable, although the mechanism of such
a phenomenon is unknown. Cell death in the core
is rapid whereas cells in the penumbra may survive
up to several hours. 
A substantial amount of information is now
available from positron emission tomography (PET)
and MRI studies, which show that in some patients
potentially salvageable ischemic tissue exists for
many hours after stroke onset [66-82]. The
availability of PET is limited and the technique is
time-consuming, and hence it is likely to remain an
imaging tool restricted to research centers.
Diffusion-perfusion MRI and CT perfusion studies
are now widely available at many clinical facilities.
The PWI-DWI mismatch on MRI provides a rapid
imaging marker of potentially salvageable ischemic
tissue which can be widely used to identify
potentially treatable ischemic stroke patients
irrespective of the time from onset. Hopefully, using
this approach, patient selection will be based on
a pathophysiological assessment rather than rigid
time window periods. This should expand the
therapeutic time window for both thrombolysis and
neuroprotection. 
In future, absolute value maps of perfusion and
diffusion are likely to be generated, and estimations312 Arch Med Sci 3, June / 2010
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provided as to what percentage of ischemic tissue
is highly likely to be irreversibly injured, what
percentage is not at risk for infarction, and what
percentage is at risk for infarction but can be
salvaged with appropriate treatment. The availa  -
bility of such a 3-compartment assessment of
ischemic tissue will move acute stroke treatment
into a new era of time-independent decision-
making. 
DWI may delineate infarcted brain tissue within
minutes, although there is growing evidence that
in the very early stage of stroke there may be
reversible DWI changes in up to 45% of patients
experiencing recanalization after treatment with
recombinant tissue plasminogen activator (rt-PA).
However, in most instances, these lesion reversals
are only minor or partial and frequently not
permanent. There are contradictory data as to
whether a DWI/apparent diffusion coefficient
threshold for irreversible ischaemia exists. PWI
defines the area of cerebral hypoperfusion. The
absolute volume difference or ratio of PWI to DWI
reveals the ischemic tissue at risk of irreversible
infarction. The presence of vessel occlusion on
magnetic resonance angiography (MRA) is
associated with a PWI/DWI mismatch. Therefore,
stroke MRI defines the ideal candidate for
thrombolysis. In addition, early recanalization
achieved by thrombolysis results in significantly
smaller infarcts and a better clinical outcome. The
concept of diffusion/perfusion mismatch has
received the most attention and is best
demonstrated by the Diffusion and Perfusion
Imaging Evaluation for Understanding Stroke
Evolution (DEFUSE) study [83]. DEFUSE showed that
patients with a perfusion abnormality that was at
least 20% of their diffusion abnormality on initial
MRI seemed to benefit from delayed (3-6 h)
thrombolysis/recanalization compared with patients
who did not recanalize and those who did not have
a diffusion/perfusion mismatch. The concept of
diffusion/perfusion mismatch as a target for
recanalization is currently being tested in
a prospective, randomized, controlled trial known
as MR RESCUE. In this study, patients are
randomized within 8 h onset to either endovascular
recanalization with a MERCI Retriever or standard
care. Randomization is stratified by the initial
magnetic resonance diffusion/perfusion pattern. 
A comparison of computed tomography/computed
tomography angiography/CTA source image analysis
(CT/CTA/CTA-SI) findings with MRI (DWI) and MRA
reveals equal accuracy of CTA and MRA, close to
equal accuracy of infarct volumes according to 
CTA-SI compared with DWI, and a predictive value
of poor collaterals for infarct growth. Therefore,
CT/CTA/CTA-S1 may provide information similar to
that of the PWI/DWI mismatch concept. 
There is growing evidence for emerging
strategies that have the potential to extend cerebral
reperfusion therapy beyond the 3-h/4.5-h time
window. Approaches to this include: (i) intra-arterial
(IA) pharmacological reperfusion approaches,
combined intravenous–intra-arterial (IV/IA) fibri  no  -
lysis and combined fibrinolytics and glycoprotein
(Gp)IIb/IIIa agents; (ii) emerging endovascular
mechanical reperfusion strategies including IA
thrombectomy (clot retrieval devices and suction
thrombectomy devices), mechanical disruption
(micro-guidewire passage, laser photo-acoustic
emulsification, primary intracranial angioplasty); 
(iii) augmented fibrinolysis by endovascular
ultrasound; (iv) multimodal imaging with MRI or CT
to rapidly assess the infarct core, penumbra, site of
vessel occlusion and hemorrhagic propensity of the
tissue, enabling improved selection of patients for
reperfusion therapy beyond any arbitrary fixed time
window; (v) newer thrombolytic agents; (vi)
adjunctive therapies such as neuroprotectants. 
Given all the presently available data, if we follow
the guidelines of intravenous thrombolysis within
the first 3 h/4.5 h after stroke onset for all AIS, we
have a less than 20% chance of reopening large
arteries (ICA, MCAM1, or BA, especially proximal BA
occlusions) with IV t-PA vs. a 60-70% chance with
IA thrombolysis. While it is not entirely clear if
reopening blood vessels equals reperfusion, all the
present data from meta-analysis of thrombolytic
trials, retrospective large database analysis and
case series suggest that it does. Why else would
we have resolution of perfusion deficits and
shrinkage/stabilization hyperintensity on diffusion
weighted imaging after successful establishment
of reflow? 
Maybe it is time to reassess our options when
we consider the mode of thrombolysis for AIS
presenting within the 3- and 4.5-h time window.
The paradigm may be as follows. In centers with
adequate infrastructure and know-how, in patients
presenting with AIS: perform CT/CTA/perfusion CT
or MRI/MRA/perfusion MRI. If patients have a major
large vessel occlusion (ICA, M1 or BA) consider IA
treatment. If significant delays in starting IA are
expected, IV thrombolysis can be initiated followed
by IA treatment if the patient fails to recanalize. For
all other cases consider IV thrombolysis. 
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